Kataoka T, Oh-hashi F
Cancer Res. 1985 Jul;45(7):2962-6.
Treatment with both L1210 murine leukemia cell vaccine (L1210 vaccine) and 6-mercaptopurine (6-MP) induced antitumor effector cells in the spleen and peritoneal cavity of L1210-bearing mice. The in vivo neutralization test showed that the spleen cells and peritoneal cells of mice treated with both agents, but not with either agent alone, prolonged the life span of animals simultaneously inoculated i.p. with live L1210 cells. These results indicate that these antitumor cells were associated with the augmented therapeutic response in L1210-bearing mice treated with both agents. The neutralizing activity of peritoneal cells was located to a fraction not adhering to plastic flasks and abolished by the treatment of anti-Thy 1.2 antibody and complement, indicating that they were T-cells. The in vitro antiproliferation test confirmed these observations. The spleen cells and peritoneal T-cells of these mice suppressed L1210 proliferation. Their activity was tumor specific since they suppressed the in vitro proliferation of L1210 but not P388 and L5178Y cells. The in vivo association of antitumor T-cells with the augmented therapeutic effect was substantiated by the finding that rabbit anti-mouse thymocyte globulin abolished the induced therapeutic effect.
用L1210小鼠白血病细胞疫苗（L1210疫苗）和6-巯基嘌呤（6-MP）联合处理可在荷L1210小鼠的脾脏和腹腔中诱导抗肿瘤效应细胞。体内中和试验表明，联合使用这两种药物处理的小鼠的脾细胞和腹腔细胞，而非单独使用任一药物处理的小鼠的脾细胞和腹腔细胞，可延长同时经腹腔接种活L1210细胞的动物的寿命。这些结果表明，这些抗肿瘤细胞与联合使用这两种药物处理的荷L1210小鼠增强的治疗反应相关。腹腔细胞的中和活性定位于不粘附于塑料培养瓶的一部分细胞，并且经抗Thy 1.2抗体和补体处理后被消除，表明它们是T细胞。体外抗增殖试验证实了这些观察结果。这些小鼠的脾细胞和腹腔T细胞抑制L1210的增殖。它们的活性具有肿瘤特异性，因为它们抑制L1210的体外增殖，但不抑制P388和L5178Y细胞的增殖。兔抗小鼠胸腺细胞球蛋白消除了诱导的治疗效果，这一发现证实了体内抗肿瘤T细胞与增强的治疗效果之间的关联。
